June 2, 2009
Genzyme Corp. (Nasdaq: GENZ) announced today that it has completed the transaction with Bayer HealthCare to acquire the worldwide rights to Campath®/MabCampath® (alemtuzumab), giving Genzyme primary responsibility for the development and commercialization of this promising multiple sclerosis (MS) therapeutic candidate. Genzyme is conducting two rapidly progressing phase 3 studies of alemtuzumab in relapsing-remitting MS patients.
March 16, 2009
Following the February 2009 approval by Health Canada, Genzyme Canada today announced the availability of Synvisc-One™ (Hylan GF-20), a single injection viscosupplement approved for Osteoarthritis (OA) of the knee. Synvisc-One is the latest addition to a growing Synvisc® family of products used to treat Osteoarthritis including: a single 2mL injection for the hip, shoulder and ankle, and a 3 X 2mL dosage format for the knee. Osteoarthritis is a common, debilitating disease that affects approximately 1 in 10 Canadians.1
Last Updated: 12/3/2015

Genzyme Canada
Canadian Office 
2700 Matheson Blvd. East 
West Tower, Suite 800 
Mississauga, Ontario L4W 4V9 
Tel: +1 905 625 0011 
Fax: +1 905 625 7811 
Toll Free: +1 877 220 8918 

Genzyme Medical Information 
Tel: +1 800 589 6215

If this is an emergency, please contact your local emergency department.

Ethics inquiries 
Tel: +1 800 648 1297

This Is Genzyme
Discover more about Genzyme's purpose, legacy, and innovation in our corporate brochure.

Explore opportunities at a company that's as committed to our employees as we are to our patients.